Sensirion (SENS) H1 2026 earnings summary

Executive summary

• Revenue reached CHF 179 million, up 7% in local currencies but down 3% in Swiss francs due to FX effects, with all four end markets contributing to growth, especially medical, automotive, and consumer segments.

• Profitability remained robust, with EBITDA margin at 19.5% and gross margin expanding to 52.6%.

• Net income surged 82% year-over-year to CHF 18.9 million, driven by normalized financial results.

• Operating cash flow rose 20% to CHF 34 million, supporting a 14% increase in net cash to CHF 81.7 million.

• Strong execution in H1 2026 led to raised full-year guidance and reinforced confidence in long-term growth strategy.

Financial highlights

• Gross margin improved to 52.6% from 51.5% a year ago, aided by operating leverage and favorable product mix.

• EBITDA was CHF 34.9 million (19.5% margin), stable versus prior year.

• Net profit surged 82% year-over-year to CHF 18.9 million, reflecting normalized financial results.

• Operating cash flow reached CHF 34 million, with free cash flow at CHF 10.6 million after elevated CapEx.

• Equity ratio stands at 80.8%, providing strong financial flexibility.

Outlook and guidance

• Revenue guidance for 2026 raised to CHF 345–365 million, reflecting 8–14% local currency growth.

• EBITDA margin expected at the upper half of the mid to high teens range.

• Growth areas established in recent years are gaining momentum and expected to contribute more significantly.

• Guidance range reflects market volatility and customer inventory management dynamics.